Medytox, Temporary Manufacturing and Sales Suspension Order for 'Innotox Injection'
[Asia Economy Reporter Park Jun-yi] Medytox announced on the 23rd that it has received a provisional manufacturing and sales suspension order for pharmaceuticals from the Daejeon Food and Drug Safety Administration.
Medytox explained, "We were notified by the Ministry of Food and Drug Safety of violations of the Pharmaceutical Affairs Act regarding 'Innotox Injection (Clostridium botulinum toxin type A)', which we manufacture and sell," and added, "We have received a provisional manufacturing and sales suspension order pursuant to Article 71 of the Pharmaceutical Affairs Act."
Hot Picks Today
"After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- [Breaking] Trump: "I Don't Think There Is a Conflict in Taiwan... Made No Promises"
- Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Medytox plans to file for suspension of effectiveness and initiate cancellation litigation regarding the manufacturing and sales suspension order.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
